Bellevue Group AG Boosts Stake in IQVIA Holdings Inc. (NYSE:IQV)

Bellevue Group AG lifted its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 0.9% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,336 shares of the medical research company’s stock after purchasing an additional 76 shares during the quarter. Bellevue Group AG’s holdings in IQVIA were worth $2,108,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently modified their holdings of the company. AdvisorNet Financial Inc raised its stake in shares of IQVIA by 327.6% in the fourth quarter. AdvisorNet Financial Inc now owns 124 shares of the medical research company’s stock worth $29,000 after purchasing an additional 95 shares during the last quarter. Rise Advisors LLC bought a new stake in shares of IQVIA in the first quarter worth $31,000. Riverview Trust Co bought a new stake in shares of IQVIA in the first quarter worth $32,000. Activest Wealth Management bought a new stake in shares of IQVIA in the fourth quarter worth $35,000. Finally, Covestor Ltd grew its holdings in shares of IQVIA by 45.3% in the first quarter. Covestor Ltd now owns 154 shares of the medical research company’s stock worth $39,000 after acquiring an additional 48 shares during the period. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Price Performance

Shares of NYSE:IQV traded down $1.95 during mid-day trading on Monday, reaching $237.72. The stock had a trading volume of 455,731 shares, compared to its average volume of 1,086,482. The company has a current ratio of 0.85, a quick ratio of 0.85 and a debt-to-equity ratio of 1.80. The company has a market cap of $43.34 billion, a P/E ratio of 32.74, a price-to-earnings-growth ratio of 2.26 and a beta of 1.49. IQVIA Holdings Inc. has a 1 year low of $167.42 and a 1 year high of $261.73. The business’s 50 day moving average price is $220.23 and its 200 day moving average price is $229.55.

IQVIA (NYSE:IQV) last posted its earnings results on Monday, July 22nd. The medical research company reported $2.64 EPS for the quarter, topping analysts’ consensus estimates of $2.57 by $0.07. IQVIA had a return on equity of 28.59% and a net margin of 9.39%. The company had revenue of $3.81 billion for the quarter, compared to the consensus estimate of $3.79 billion. During the same period in the previous year, the business earned $2.22 earnings per share. The firm’s revenue for the quarter was up 2.3% on a year-over-year basis. Research analysts expect that IQVIA Holdings Inc. will post 10.21 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently commented on IQV shares. UBS Group lifted their price objective on IQVIA from $295.00 to $300.00 and gave the stock a “buy” rating in a report on Tuesday, July 23rd. Barclays lifted their price objective on IQVIA from $255.00 to $275.00 and gave the stock an “overweight” rating in a report on Tuesday, July 23rd. Evercore ISI lifted their price objective on IQVIA from $230.00 to $270.00 and gave the stock an “outperform” rating in a report on Tuesday, July 23rd. The Goldman Sachs Group began coverage on IQVIA in a report on Thursday, June 6th. They set a “buy” rating and a $270.00 price target for the company. Finally, StockNews.com raised IQVIA from a “hold” rating to a “buy” rating in a report on Monday, July 15th. Four analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. Based on data from MarketBeat.com, IQVIA has a consensus rating of “Moderate Buy” and an average target price of $263.56.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.